ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Glaxo To Buy Genelabs Technologies

by Marc S. Reisch
November 3, 2008 | APPEARED IN VOLUME 86, ISSUE 44

GlaxoSmithKline has reached a definitive agreement to buy Genelabs Technologies for $57 million. Genelabs is a Redwood City, Calif.-based drug discovery firm now focusing on novel compounds that selectively inhibit replication of the hepatitis C virus. The two firms already have a partnership to develop a vaccine against hepatitis E.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment